The Efficacy, Safety, and Pharmacology of a Ghrelin O-Acyltransferase Inhibitor for the Treatment of Prader-Willi Syndrome.

Jennifer L MillerAndrea Z LaCroixLynne M BirdAshley H ShoemakerAndrea HaqqCheri L DealKristie A ClarkMichael H AmesJeffrey G SuicoAmparo de la PeñaCaroline Fortier

Published in: The Journal of clinical endocrinology and metabolism (2022)

GLWL-01 is safe and well tolerated. Pharmacological parameters confirmed the inhibition of GOAT following administration of GLWL-01. Patients' eating behaviors, BMI, blood glucose, and total cholesterol, among other similar measures, were not modified.

Keyphrases

blood glucose
ejection fraction
newly diagnosed
growth hormone
body mass index
prognostic factors
physical activity
glycemic control
weight loss
patient reported outcomes
metabolic syndrome
adipose tissue
combination therapy